• Vaccine Ontology ID: VO_0004515
• Type: DNA vaccine
• Status: Research
• gapA gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pcDNA3.1 Directional TOPO vector (pcDNA3.1D/V5-His-TOPO) (Fu et al., 2012)
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Four to five week old female BALB/c mice were divided randomly into three groups (30 mice per group): one group was injected intramuscularly in the hind thigh muscle with 100 μg of plasmid dissolved in 100 μl PBS; the other two groups were injected with pcDNA 3.1 vector only as negative control or PBS as blank control. Mice received a vaccination boost of an equivalent dose on day 14 and 28 following the first immunization (Fu et al., 2012).
• Vaccine Immune Response Type: VO_0000286
• Immune Response: Although IgG analysis showed production of both IgG1 and IgG2, the higher levels of IgG1 indicated the dominance of Th2 response over Th1 response (Fu et al., 2012).
• Challenge Protocol: Two weeks after the second vaccination boost, mice immunized with pCgap were divided into groups 1 and 2 (12 mice/group). The mice from group 1 were challenged intraperitoneally with a lethal dose of 3.0 × 10^9 CFU of H. parasuis SH0165 strain and the mice from group 2 were challenged intraperitoneally with a lethal dose of 3.0 × 10^9 CFU of H. parasuis MD0322 strain. Mice were monitored for seven days post-challenge, and morbidity and mortality were recorded (Fu et al., 2012).
• Efficacy: The groups vaccinated with the pCgap vaccine exhibited 83.3% and 50% protective efficacy against the H. parasuis MD0322 serovar 4 or SH0165 serovar 5 challenges, respectively (Fu et al., 2012).